What is the treatment for neurologic crises in AIP?
Therapy is directed at modifying the biochemical abnormalities found in the disease, including overproduction of the neurotoxin delta-aminolevulinic acid and heme deficiency.
Intravenous administration of hematin increases available heme and downregulates the patient’s abnormal heme biosynthetic pathway, thus reducing delta-aminolevulinic acid levels.
Prevention of crises is the primary goal in treating patients with AIP.
Education of patients to the many precipitants of acute attacks is necessary for their survival.
